Issue link: https://uberflip.scri.com/i/1531660
0206/25SCR020-1/R3RGB Abstract & Presentation Calendar Tandem Transplantation and Cellular Therapy Meetings 2025 2 Thursday Wednesday Friday Saturday THURSDAY, FEBRUARY 13 TH 7:00am - 8:00am Honolulu Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 7:00 - 8:00am 7:10 - 7:20am Ballroom A Presenter Clinical Consult 1: Goals of Care With Modern SCD Therapy Frangoul H Tandem Thursday Breakfast Symposium: Innovation Takes Shape in SCD: Rewriting Management Principles with Gene Therapy and Revisiting the Role of HSCT 7:00 - 8:00am 7:35 - 7:50am Ballroom A Presenter Clinical Consult 3: Practical Experience With Gene Therapy in SCD Frangoul H Tandem Thursday Breakfast Symposium: Innovation Takes Shape in SCD: Rewriting Management Principles with Gene Therapy and Revisiting the Role of HSCT 7:00 - 8:00am Ballroom A Chair Chair Frangoul H Tandem Thursday Breakfast Symposium: Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT THURSDAY, FEBRUARY 13 TH 1:45pm - 4:45pm Honolulu Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 1:45 - 3:15pm Ballroom C Chair Chair Majhail N ASTCT Spotlight Session: ASTCT 6th International Workshop 3:15 - 3:45pm 3:15 - 3:25pm 312 Oral 111 Safety and Efficacy Results from a Randomized, Double-Blind, Placebo- Controlled Cohort 2 of a Phase 1b Study of an Investigational Live Biotherapeutic, SER-155, in Adults Undergoing Allo-HCT Ponce D Farhadfar N (ID) Best Abstracts 3:15 - 4:45pm 3:45 - 4:00pm Ballroom B Oral 39 Determinants of Immune Suppression Discontinuation in the Modern Era: A CIBMTR Analysis of 18,642 Subjects Pidala J Farhadfar N Oral Abstract - Session E - GVHD Clinical 3:15 - 4:45pm 4:30 - 4:45pm Ballroom C Oral 48 A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort (Arm C) Dholaria B Cruz JC, Ramakrishnan A Oral Abstract - Session F - Myeloma and Lymphoma